Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TQC2938 in Healthy Adults
NCT06449859Phase 1Active, not recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Jun 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TQC2938 in asthma (10 arms), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Adverse events (AEs), Serious adverse events (SAEs) and 1 more. Started Jun 2023; status: active, not recruiting.
02
Drugs
TQC2938
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06449859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06449859.